Introduction
The launch of serotonin antagonists which are largely aimed at treating sleep
maintenance is set to make a substantial impact on the insomnia market, which
will increase in value across the seven major markets from $6.1 billion in
2006 to $7.7 billion in 2016.
Scope
- Analysis of patient potential, unmet needs and clinical trial design in
insomnia
- Overview of drugs in late- and early-stage clinical development; with
analysis of key companies involved in the R&D pipeline
- Detailed profiles of key compounds in development for use in insomnia,
with forecasts of drug revenues to 2016
- Discussion of Sanofi-Aventis' and Neurocrine' s strategies, and insight
from key industry opinion leaders
Highlights
Serotonin receptor antagonists are the most prevalent drug class in the
late-stage insomnia pipeline. This represents a move away from the GABA
agonists which currently dominate the market. Datamonitor predicts that
serotonin antagonist companies will be important players in the market in the
future, led by Sanofi-Aventis' eplivanserin.
The majority of pipeline drugs are being investigated for sleep maintenance as
opposed to sleep onset insomnia and there is a trend towards the development
of drugs for the treatment of co-morbid disorders.
In March 2007, Merck & Co. and Lundbeck discontinued development of their
Phase III drug, gaboxadol, due to disappointing trial results. Although this
is a considerable blow to Lundbeck, the reduction in competition is positive
news for current and future insomnia market players.
Reasons to Purchase
- Understand unmet needs in the insomnia market based on key opinion leader
comments
- Benchmark key late-stage insomnia compounds against current market leaders
- Assess the global (US, Japan, five major EU) sales forecasts of key
late-stage pipeline drugs; and examine their clinical and commercial potential
View Cart
